Project dates: September 2019 - July 2024
Principal Investigator: Carrico A (Contact PI)
Principal Investigator: Horvath K
This two-arm randomized clinical trial of a 6-month mHealth intervention, for 350 HIV-positive MSM who use stimulants, seeks to improve viral load suppression at 6 months and determine whether any gains are maintained at month 12. If effective, START is scalable to reach a broader population of HIV+ MSM who use stimulants and may be adapted to clinic- and community-based settings.
This supplement will provide some of the first data regarding whether and how those with co- occurring meth use and HIV are more vulnerable to SARS-CoV-2 infection. This represents a crucial first step to identifying high priority populations that will directly inform the development bio-behavioral interventions to mitigate risk for COVID-19. These findings will also inform targeted public health efforts to “flatten the curve” of community-level SARS-CoV-2 transmission in this rapidly evolving COVID-19 pandemic.Abstract on NIH RePORTER